Lomilan, tablets 10 mg 7 pcs

Lomilan is an antihistamine, anti-allergic.

Pharmacodynamics

Loratadine refers to antihistamines of systemic action, blockers of H₁-histamine receptors.

Loratadine has anti-allergic, antipruritic, antiexudative action. It reduces capillary permeability, prevents the development of tissue edema, relieves spasms of smooth muscles. Antiallergic effect shall develop within 30 minutes after the drug intake, it reaches its maximum effect after 8-12 hours and lasts for 24 hours.

It does not affect CNS and is not addictive.

Pharmacokinetics

Loratadine is quickly and completely absorbed from the gastrointestinal tract. The presence of food slows absorption.C_max in serum is reached within 1 h after ingestion. Binding to plasma proteins is more than 95%. It is metabolized in the liver with the formation of the active metabolite descarboethoxyloratadine.

It does not penetrate through the HEB. T_1/2 is about 8 h, increases in the elderly and in chronic alcoholism. It is excreted with the bile and the kidneys.

In chronic renal failure and hemodialysis the pharmacokinetics are virtually unchanged.

Indications

Prevention and treatment of the following diseases and conditions:

Active ingredient

Composition

How to take, the dosage

At the mouth with water or milk, can be taken with food. If necessary, the tablet may be chewed.

Adults and children over 12 years of age – 2 dosage spoons (10 ml) once a day; children from 2 to 12 years of age with body weight over 30 kg – 2 dosage spoons (10 ml) once a day; with body weight less than 30 kg – 1 dosage spoon (5 ml) once a day.

Adults and children over 12 years of age – 10 mg (1 tablet) 1 time daily; children from 3 to 12 years of age with body weight over 30 kg – 10 mg (1 tablet) 1 time daily; with body weight less than 30 kg – 5 mg (1/2 tablet) 1 time daily.

In patients with hepatic impairment a reduced daily dose for adults and children with body weight over 30 kg the dose is 10 mg (2 dosage spoons of suspension or 1 tablet) once daily.

In children under 12 years of age the use of the suspension is recommended.

The duration of treatment depends on the duration of manifestation of symptoms of the disease. If the patient’s condition does not improve within 3 days after the start of treatment, then loratadine is ineffective.

Patients of advanced age or with renal insufficiency do not require dose adjustment.

Patients with severe renal insufficiency (creatinine Cl In adults and children from 6 years of age, the starting dose should be 10 mg (2 dosage spoons of suspension or 1 tablet) every other day; in children from 3 years, 5 mg (1 dosage spoon of suspension or 1/2 tablet) every other day.

Interaction

The simultaneous use of microsomal oxidation inducers (phenytoin, ethanol, barbiturates, rifampicin, tricyclic antidepressants) reduces the effectiveness of loratadine.

Possible interaction of the drug with cytochrome isoenzyme inhibitors such asCYP3A4 or CYP2D6 (ketoconazole, quinidine, itraconazole, erythromycin, fluoxetine) increases the plasma concentration of Lomilan®, which may lead to increased side effects of the drug.

Special Instructions

The drug should be discontinued at least two days prior to skin allergy testing because Lomilan® may affect the results.

Special precautions for disposal of unused medication

There is no need for special precautions when disposing of unused Lomilan®.

Contraindications

With caution: hepatic failure; severe renal failure (creatinine Cl

Side effects

According to the World Health Organization (WHO) adverse reactions are classified according to their frequency of development as follows: very common (≥1/10) common (≥1/100 < 1/10) infrequent (≥1/1000 < 1/100) rare (≥1/10000 < 1/1000) and very rare (< 1/10000); frequency is unknown – according to available data it was impossible to determine the incidence.

Immune system disorders Very rare: hypersensitivity reactions (including angioedema and anaphylactic reactions).

Nervous system disorders frequently: headache drowsiness increased nervous excitability increased fatigue; infrequent: insomnia; very rare: dizziness seizures.

Cardiovascular system disorders very rare: tachycardia palpitations syncope arrhythmia.

Gastrointestinal tract infrequent: increased appetite; very rare: nausea dry mouth gastritis.

Liver and biliary tract very rarely: impairment of liver function.

The skin very rare: allergic reactions (rash) alopecia.

In addition to the above reactions in children, a sedative effect may develop.

NSNS adverse events (headache (27%) nervousness (23%) and fatigue (1%)) were detected more often than when taking placebo (“pacifier”).

Overdose

Symptoms: headache, drowsiness, palpitations, which may last for a long time.

Treatment: If an excessive amount of the drug Lomilan® is taken, it is recommended to flush the stomach and prescribe an adsorbent (activated charcoal). There is no specific antidote. Lomilan® is not excreted by hemodialysis. It is also currently unknown whether Lomilan® is excreted by peritoneal dialysis. Medical follow-up of the patient should be performed after emergency therapy.

Pregnancy use

The safety of using the drug Lomilan® during pregnancy has not been established; therefore, the use of the drug during this period is contraindicated.

Lomilan® is excreted into the breast milk, so if it is necessary to use the drug during lactation, it is necessary to consider stopping breastfeeding.

Similarities